Check point inhibitors in peri-operative non small cell lung cancer strategy

J. Mazieres (Toulouse, France)

Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?

Number: 8

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Mazieres (Toulouse, France). Check point inhibitors in peri-operative non small cell lung cancer strategy. ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Check point inhibitors in advanced non small cell cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017
Non small cell lung cancer: options and outcome of treatment beyond second line Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
Surgery for non small cell lung cancer (NSCLC) and functional limits: is there a possible beneficial role of preoperative pulmonary rehabilitation? Source: Eur Respir J 2004; 24: Suppl. 48, 522s Year: 2004
Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009
Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Surgical treatment of small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 172s Year: 2005
Systemic treatment of small cell lung cancer Source: Annual Congress 2008 - PG6 - Thoracic oncology: new treatments for thoracic malignancies (other than nonsmall cell lung cancer) Year: 2008
Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Radiotherapy in small cell lung cancer: patient options Source: Virtual Congress 2020 – Thoracic oncology Year: 2020
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Causes of death in inoperable non small cell lung cancer (NSCLC)-retrospective study Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011